Effect of ruxolitinib supplementation in enhancing neurogenesis via gliogenesis suppression in foetal mouse brain development

JAK-STAT pathway is important in regulating gliogenesis in the brain. Dysregulation of this pathway leads to abnormality in brain development as seen in Down syndrome individuals’ predominantly low initial neuron-glia ratio in early infancy. Thus, suppression of JAK-STAT pathway would be advantageou...

Full description

Saved in:

Bibliographic Details
Main Author:	Hamzah, Hamizun
Format:	Thesis
Language:	English
Published:	2019
Subjects:	Neuroglia - physiology Janus Kinases
Online Access:	http://psasir.upm.edu.my/id/eprint/98051/1/FPSK%28m%29%202020%2045%20UPMIR.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-upm-ir.98051
record_format	uketd_dc
spelling	my-upm-ir.980512022-07-13T06:36:21Z Effect of ruxolitinib supplementation in enhancing neurogenesis via gliogenesis suppression in foetal mouse brain development 2019-05 Hamzah, Hamizun JAK-STAT pathway is important in regulating gliogenesis in the brain. Dysregulation of this pathway leads to abnormality in brain development as seen in Down syndrome individuals’ predominantly low initial neuron-glia ratio in early infancy. Thus, suppression of JAK-STAT pathway would be advantageous to reverse gliogenesis towards potentially enhance neurogenesis of which may serve as an essential building block for intellectual capability in Down syndrome individuals. To date, there is only one United State Food and Drug Administration (FDA) approved drug that targets both JAK1 and JAK2 proteins. This study aims to evaluate the toxicity and ability of ruxolitinib to suppress JAK-STAT pathway in the mouse brain when being supplemented for a long term at no observed adverse effect level (NOAEL) doses of 30mg per kilogram body-weight and below. Coherently, a control group of pregnant mice fed with methylcellulose as the vehicle and another five groups of pregnant mice were treated daily with different doses of ruxolitinib (1mg, 5mg, 10mg, 15mg and 30mg per kilogram body weight) dissolved in methylcellulose via oral administration during pregnancy E7.5 through E21.5 before delivery. At P1.5 post-delivery, multiple organs were harvested from mothers such as blood, liver, kidney and spleen for toxicity screening, whereas pup whole brains were dissected for JAK proteins analysis and gene expression. Inherently, blood biochemistry showed a normal reading on liver and kidney analytes, while histology observation revealed normal cellular morphology without discernible lymphocyte infiltration in these organs thus establishing the drug, ruxolitinib is non-toxic for a long-term administration on the pregnant mouse when administering at NOAEL doses. Subsequently, western blot analysis of the P1.5 brain lysates showed no significant differences in beta-tubulin III (Tuj1) for neuronal cells in all treated groups when compared to the untreated group. However, a significant reduction in glial fibrillary acidic protein (GFAP) for glial cells was observed at 30mg/kg ruxolitinib-treated group. However, none of the phosphorylated JAK1 and JAK2 were seen reduced in P1.5 brain suggesting JAK-STAT signalling pathway may not have been effectively targeted. The findings are subjected to further analyses, and when comprehensively validated, the application of this study would institute prepregnancy prescription of ruxolitinib as supplementation to expecting mothers of late maternal age who are at high risk of having a baby with developmental disorders such as Down syndrome. Neuroglia - physiology Janus Kinases 2019-05 Thesis http://psasir.upm.edu.my/id/eprint/98051/ http://psasir.upm.edu.my/id/eprint/98051/1/FPSK%28m%29%202020%2045%20UPMIR.pdf text en public masters Universiti Putra Malaysia Neuroglia - physiology Janus Kinases Ling, Michael King Hwa
institution	Universiti Putra Malaysia
collection	PSAS Institutional Repository
language	English
advisor	Ling, Michael King Hwa
topic	Neuroglia - physiology Janus Kinases
spellingShingle	Neuroglia - physiology Janus Kinases Hamzah, Hamizun Effect of ruxolitinib supplementation in enhancing neurogenesis via gliogenesis suppression in foetal mouse brain development
description	JAK-STAT pathway is important in regulating gliogenesis in the brain. Dysregulation of this pathway leads to abnormality in brain development as seen in Down syndrome individuals’ predominantly low initial neuron-glia ratio in early infancy. Thus, suppression of JAK-STAT pathway would be advantageous to reverse gliogenesis towards potentially enhance neurogenesis of which may serve as an essential building block for intellectual capability in Down syndrome individuals. To date, there is only one United State Food and Drug Administration (FDA) approved drug that targets both JAK1 and JAK2 proteins. This study aims to evaluate the toxicity and ability of ruxolitinib to suppress JAK-STAT pathway in the mouse brain when being supplemented for a long term at no observed adverse effect level (NOAEL) doses of 30mg per kilogram body-weight and below. Coherently, a control group of pregnant mice fed with methylcellulose as the vehicle and another five groups of pregnant mice were treated daily with different doses of ruxolitinib (1mg, 5mg, 10mg, 15mg and 30mg per kilogram body weight) dissolved in methylcellulose via oral administration during pregnancy E7.5 through E21.5 before delivery. At P1.5 post-delivery, multiple organs were harvested from mothers such as blood, liver, kidney and spleen for toxicity screening, whereas pup whole brains were dissected for JAK proteins analysis and gene expression. Inherently, blood biochemistry showed a normal reading on liver and kidney analytes, while histology observation revealed normal cellular morphology without discernible lymphocyte infiltration in these organs thus establishing the drug, ruxolitinib is non-toxic for a long-term administration on the pregnant mouse when administering at NOAEL doses. Subsequently, western blot analysis of the P1.5 brain lysates showed no significant differences in beta-tubulin III (Tuj1) for neuronal cells in all treated groups when compared to the untreated group. However, a significant reduction in glial fibrillary acidic protein (GFAP) for glial cells was observed at 30mg/kg ruxolitinib-treated group. However, none of the phosphorylated JAK1 and JAK2 were seen reduced in P1.5 brain suggesting JAK-STAT signalling pathway may not have been effectively targeted. The findings are subjected to further analyses, and when comprehensively validated, the application of this study would institute prepregnancy prescription of ruxolitinib as supplementation to expecting mothers of late maternal age who are at high risk of having a baby with developmental disorders such as Down syndrome.
format	Thesis
qualification_level	Master's degree
author	Hamzah, Hamizun
author_facet	Hamzah, Hamizun
author_sort	Hamzah, Hamizun
title	Effect of ruxolitinib supplementation in enhancing neurogenesis via gliogenesis suppression in foetal mouse brain development
title_short	Effect of ruxolitinib supplementation in enhancing neurogenesis via gliogenesis suppression in foetal mouse brain development
title_full	Effect of ruxolitinib supplementation in enhancing neurogenesis via gliogenesis suppression in foetal mouse brain development
title_fullStr	Effect of ruxolitinib supplementation in enhancing neurogenesis via gliogenesis suppression in foetal mouse brain development
title_full_unstemmed	Effect of ruxolitinib supplementation in enhancing neurogenesis via gliogenesis suppression in foetal mouse brain development
title_sort	effect of ruxolitinib supplementation in enhancing neurogenesis via gliogenesis suppression in foetal mouse brain development
granting_institution	Universiti Putra Malaysia
publishDate	2019
url	http://psasir.upm.edu.my/id/eprint/98051/1/FPSK%28m%29%202020%2045%20UPMIR.pdf
_version_	1747813832995110912

Effect of ruxolitinib supplementation in enhancing neurogenesis via gliogenesis suppression in foetal mouse brain development

Similar Items